MIR22HG

From WikiProjectMed
Jump to navigation Jump to search
MIR22HG
Identifiers
AliasesMIR22HG, C17orf91, MIR22 host gene
External IDsGeneCards: MIR22HG
Orthologs
SpeciesHumanMouse
Entrez

84981

n/a

Ensembl

ENSG00000186594
ENSG00000282800

n/a

UniProt

Q0VDD5

n/a

RefSeq (mRNA)

NM_001001870
NM_032895

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)Chr 17: 1.71 – 1.72 Mbn/a
PubMed search[2]n/a
Wikidata
View/Edit Human

MIR22HG (MIR22 host gene), also known as C17orf91,[3] MGC14376,[4] MIRN22, hsa-mir-22, and miR-22[5] is a human gene that encodes a noncoding RNA (ncRNA).This RNA molecule is not translated into a protein but nonetheless may have important functions.

MIR22HG ncRNA is greater than 200 nucleotides in length and therefore informally classified as a long non-coding RNA, i.e. lncRNA. The MIR22HG gene is located at band 13.3 on the short (or "p") arm of chromosome 17. It is expressed in each of the 27 human tissues tested.[3]

Function

Many lncRNAs regulate diverse processes including cellular metabolism, proliferation, movement, differentiation (i.e. change of a cell from one type to another, usually more mature, cell type), apoptosis (i.e. programmed cell death), and the expression of various genes through chromatin remodeling, genomic imprinting, modulating the actions of other RNAs, and various other ways.[6] The normal actions and functions of the MIR22HG gene are complex and have not been fully elucidated, but its primary function may be as a tumor suppressor gene.[7] It is involved in the regulation of several signaling pathways including Wnt/β-catenin, epithelial-mesenchymal transition (EMT), notch, and STAT3.[7]

Clinical significance

When overexpressed, it acts as a tumor suppressor gene in many cancer types but in a few cancer types it acts as an oncogene, i.e. a tumor promotor gene: MIR22HG gene's impact on various cancers is strictly dependent on the type of cancer in which it operates.[8]

The roles or the MIR22HG gene in cancers have generally been evaluated by: a) next-generation sequencing to quantify the levels of MIR22HG RNA in cancer samples, samples of nearby normal tissue of the same type as the cancer, and cultured cancer cells of the same type as the cancers; b) comparing MIR22HG lncRNA levels in patients with the same cancer to the severity (e.g. aggressiveness, recurrence rate, and survival rate) of their cancers; c) determining the potential mechanisms for the MIR22HG lncRNA's actions, generally by defining the effects of varying the levels of this lncRNA on various cancer-promoting or cancer-inhibiting cell signaling pathways in cultured cancer cells; and d) determining the activity of these cell signaling pathways in cancer tissues. These studies are important because they established the levels of MIR22HG lncRNA as prognosis indicators and suggest that this lncRNA and the implicated cancerous signaling pathways are therapeutic targets for treating these cancers.[7]

Tumor-suppression

Some of the cancer types that have been associated with the MIR22HG gene and its lncRNA product acting to suppress the cancer are:

  • Non-small-cell lung cancer (NSCLC): The MIR22HG gene was down-regulated (i.e. under-expressed to give low levels of this genes lncRNA) in the NSCLC tumors of individuals who had poorer prognoses.[9] Overexpression of the MIR22HG gene in various types of NSCLC cells in culture suppressed cell proliferation and invasion and induced cell cycle arrest (i.e. blocked cell division) apparently by indirectly stimulating the production of p21, an inhibitor of cell replication.[7]
  • Thyroid cancer (TC): low levels of MIR22HG lncRNA were found in individuals with large tumor size, lymph node metastases, advanced clinical stage, shorter disease-free survival time, and poor survival times in TC. Reducing lncRNA levels using gene knockdown methods) suppressed the growth and invasiveness of TC cells in culture. Further studies suggested that these effects reflected high activity of the Hippo signaling pathway (A oncogenic pathway in TC[10]). Increasing the levels of MIR22HR lncRNA in these cultured TC cells suppressed this pathway.[7][11]
  • Lung adenocarcinoma (LAC): The levels of MIR22HG RNA were lower in LAC tumors than normal lung tissues and lower levels of this lncRNA in LAC tumor tissue were associated with poor patient survival times.[7][12][9]
  • Non-small cell lung cancer (NSCLC): Low levels of MIR22HG lncRNA in NSCLC tissues were highly associated with poor patient survival times. Increasing MIR22HG lncRNA levels in cultured NSCLC cells reduced their proliferation and invasiveness. Further NSCLC cell culture studies suggested that high levels of MIR22HG lncRNA acted by suppressing the levels of p21.[7][9]
  • Hepatocellular carcinoma (HCC): low levels of MIR22HG lncRNA in HCC tumors were associated with short overall survival and poor disease-free survival times. The suppression of lncRNA production suppressed the growth, migration and invasion of cultured HCC cells, Further culture cell studies suggested this effect was due to the increases in NCOR2 levels that were associated with decreased lncRNA levels.[7][13]
  • cholangiocarcinoma (CAA): Low levels of MIR22HG lncRNA in CCA tumors were associated with an advanced clinical stage, larger tumor size, lymph node metastasis, and poor survival times.[7][14]
  • Colorectal cancer (CRC): Low levels of MIR22HG lncRNA were found in CRC tumors compared to normal colorectal tissue. Low tumor tissue levels of this lncRNA were significantly associated with shorter patient survival times. Suppressing the levels of MIR22HG lncRNA in CRC cells increased their survival and proliferation in culture and their ability to metastasize in an animal model. Further cell culture studies suggested that low levels of MiR22HF lncRNA promote epithelial-mesenchymal transition mechanisms (that have oncogenic actions[15]) and thereby the aggressiveness of CRC.[7][16][17]
  • Gastric cancer (GC): Low levels of MIR22HG gene expression were associated with poor 5-year overall survival times in GC patients. Forced overexpression of MIR22HG lncRNA suppressed the proliferation, invasiveness, and migration of cultured GC cells. Further GC cell culture studies suggested that the suppressive effects of high MIR22HG lncRNA levels were to its indirect effects in regulating NOTCH2 (NOTCH2 appears involved in various types of cancer[18]).[7][11]
  • Prostate cancer (PC): Low MIR22HG lncRNA levels were found in PC cases that had a more aggressive and poorer prognosis as judged by Gleason scores, a shorter progression-free survival time, and an early onset of disease recurrences.[19][20]
  • Cancer of the cervix (CC): Higher tumor tissue levels of MIR22HG lncRNA were associated with better clinical prognoses in CC. Forced overexpression of this lncRNA increased apoptosis (i.e. programmed cell death) and inhibited the invasiveness of several CC cell lines in culture. The cell culture studies suggested that increased lncRNA worked by suppressing the levels of a potential oncogene,[21] IGF2BP2.[22][23]

Some reports have suggested that the MIR22HG gene acts as a tumor suppressor based on examining the effects of MIR22HG lncRNA levels on cultured cancer cell function and/or and tumor spread in animal models and/or the levels of MIR22HR lncRNA in cancer versus normal nearby tissues. However, these reports did not determine the relationship of MIR22HG levels in patients' cancer tissues to their prognoses. These reports include those on: osteosarcoma,[24] cancer of the uterus endometrium,[25] and cancer of the larynx.[26]

Tumor-promotion

  • Glioblastoma multiforme (GBM): Increased levels of MIR22HG lncRNA were associated with poor survival in GBM patients.[7] Blocking (by Gene knockdown methods) production of this lncRNA inhibited the proliferation and invasiveness of GBM cells in culture and the growth and invasiveness of these cells in a mouse mode.[27] Further cell culture studies suggested that MIR22HG lncRNA promoted the malignancy of GBM by stimulating the Wnt/β-catenin signalling pathways.[7][27]
  • Ovarian cancer (OC): Increased levels of MIR22HG lncRNA (termed C17orf91 lncRNA in published studies) were associated with shorter progression-free survival times and tended to be associated with shorter survival times in patients with OC. Suppressing the expression of MIR22HG lncRNA by using shRNA impaired the migration, invasiveness, and viability of cultured OC cells. Elevated levels of MIR22HG lncRNA were associated with increased levels of the proto-oncogene (i.e. potentially cancer-causing gene) MYC in these culture studies.[4][7]

The MIR22HG gene acted as a tumor promotor in squamous cell carcinoma of the esophagus based on studies showing that suppressing its levels in various types of cultured esophagus squamous-cell carcinoma cells inhibited their proliferation, invasiveness, and ability to form colonies and also increased their apoptosis. The cell culture studies suggested that decreasing MIR22HG lncRNA levels produced these results by decreasing the expression of STAT3, c-Myc, and PTK2.[7][28]

References

  1. ^ a b c ENSG00000282800 GRCh38: Ensembl release 89: ENSG00000186594, ENSG00000282800 – Ensembl, May 2017
  2. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. ^ a b "MIR22HG MIR22 host gene [Homo sapiens (Human)] - Gene - NCBI".
  4. ^ a b Li J, Yu H, Xi M, Lu X (August 2016). "Long noncoding RNA C17orf91 is a potential prognostic marker and functions as an oncogene in ovarian cancer". Journal of Ovarian Research. 9 (1): 49. doi:10.1186/s13048-016-0258-3. PMC 4989523. PMID 27535740.
  5. ^ "Homo sapiens MIR22 - Gene - NCBI".
  6. ^ Palazzo AF, Lee ES (2015). "Non-coding RNA: what is functional and what is junk?". Frontiers in Genetics. 6: 2. doi:10.3389/fgene.2015.00002. PMC 4306305. PMID 25674102.
  7. ^ a b c d e f g h i j k l m n o Zhang L, Li C, Su X (December 2020). "Emerging impact of the long noncoding RNA MIR22HG on proliferation and apoptosis in multiple human cancers". Journal of Experimental & Clinical Cancer Research. 39 (1): 271. doi:10.1186/s13046-020-01784-8. PMC 7712612. PMID 33267888.
  8. ^ Samimi H, Sajjadi-Jazi SM, Seifirad S, Atlasi R, Mahmoodzadeh H, Faghihi MA, Haghpanah V (2020). "Molecular mechanisms of long non-coding RNAs in anaplastic thyroid cancer: a systematic review". Cancer Cell International. 20: 352. doi:10.1186/s12935-020-01439-w. PMC 7392660. PMID 32760219.
  9. ^ a b c Su W, Feng S, Chen X, Yang X, Mao R, Guo C, Wang Z, Thomas DG, Lin J, Reddy RM, Orringer MB, Chang AC, Yang Z, Beer DG, Chen G (June 2018). "Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer". Cancer Research. 78 (12): 3207–3219. doi:10.1158/0008-5472.CAN-18-0222. PMC 6004254. PMID 29669758.
  10. ^ Carneiro TN, Bim LV, Buzatto VC, Galdeno V, Asprino PF, Lee EA, Galante PA, Cerutti JM (May 2021). "Evidence of Cooperation between Hippo Pathway and RAS Mutation in Thyroid Carcinomas". Cancers. 13 (10): 2306. doi:10.3390/cancers13102306. PMC 8151534. PMID 34065786.
  11. ^ a b Qin L, Luo JZ, Tang XL, Han CG (April 2019). "Identification of Long Noncoding RNA MIR22HG as a Novel Biomarker in Thyroid Cancer". Pathology & Oncology Research. 25 (2): 703–710. doi:10.1007/s12253-018-0521-6. PMID 30539522. S2CID 54477326.
  12. ^ Li DS, Ainiwaer JL, Sheyhiding I, Zhang Z, Zhang LW (June 2016). "Identification of key long non-coding RNAs as competing endogenous RNAs for miRNA-mRNA in lung adenocarcinoma". European Review for Medical and Pharmacological Sciences. 20 (11): 2285–95. PMID 27338053.
  13. ^ Gao L, Xiong DD, He RQ, Yang X, Lai ZF, Liu LM, Huang ZG, Wu HY, Yang LH, Ma J, Li SH, Lin P, Yang H, Luo DZ, Dang YW, Chen G (2019). "MIR22HG As A Tumor Suppressive lncRNA In HCC: A Comprehensive Analysis Integrating RT-qPCR, mRNA-Seq, And Microarrays". OncoTargets and Therapy. 12: 9827–9848. doi:10.2147/OTT.S227541. PMC 6875507. PMID 31819482.
  14. ^ Hu X, Tan Z, Yang Y, Yang P (May 2019). "Long non-coding RNA MIR22HG inhibits cell proliferation and migration in cholangiocarcinoma by negatively regulating the Wnt/β-catenin signaling pathway". The Journal of Gene Medicine. 21 (5): e3085. doi:10.1002/jgm.3085. PMID 30856284. S2CID 75136650.
  15. ^ Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP (August 2021). "Dynamic EMT: a multi-tool for tumor progression". The EMBO Journal. 40 (18): e108647. doi:10.15252/embj.2021108647. PMC 8441439. PMID 34459003.
  16. ^ Xu J, Shao T, Song M, Xie Y, Zhou J, Yin J, Ding N, Zou H, Li Y, Zhang J (March 2020). "MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer". Molecular Cancer. 19 (1): 51. doi:10.1186/s12943-020-01174-w. PMC 7055097. PMID 32127004.
  17. ^ Huang GD, Liao P, Huang YH, Wu YL, Wu Y, Chen SQ, Xiong J (January 2021). "MIR22HG Regulates the Proliferation, Epithelial-Mesenchymal Transition, and Apoptosis in Colorectal Carcinoma". Cancer Biotherapy & Radiopharmaceuticals. 36 (9): 783–792. doi:10.1089/cbr.2019.3509. PMID 33493419. S2CID 231712971.
  18. ^ Katoh M, Katoh M (February 2020). "Precision medicine for human cancers with Notch signaling dysregulation (Review)". International Journal of Molecular Medicine. 45 (2): 279–297. doi:10.3892/ijmm.2019.4418. PMC 6984804. PMID 31894255.
  19. ^ Pudova EA, Krasnov GS, Kobelyatskaya AA, Savvateeva MV, Fedorova MS, Pavlov VS, Nyushko KM, Kaprin AD, Alekseev BY, Trofimov DY, Sukhikh GT, Snezhkina AV, Kudryavtseva AV (2020). "Gene Expression Changes and Associated Pathways Involved in the Progression of Prostate Cancer Advanced Stages". Frontiers in Genetics. 11: 613162. doi:10.3389/fgene.2020.613162. PMC 7859645. PMID 33552133.
  20. ^ Shen H, Weng XD, Yang D, Wang L, Liu XH (December 2019). "Long noncoding RNA MIR22HG is down-regulated in prostate cancer". Mathematical Biosciences and Engineering. 17 (2): 1776–1786. doi:10.3934/mbe.2020093. PMID 32233607. S2CID 213414642.
  21. ^ Wang J, Chen L, Qiang P (February 2021). "The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers". Cancer Cell International. 21 (1): 99. doi:10.1186/s12935-021-01799-x. PMC 7876817. PMID 33568150.
  22. ^ Shu J, Wang D (August 2020). "Functional characterization of the long noncoding RNA MIR22HG as a tumour suppressor in cervical cancer by targeting IGF2BP2". European Review for Medical and Pharmacological Sciences. 24 (15): 7953–7962. doi:10.26355/eurrev_202008_22478. PMID 32767321. S2CID 221078465.
  23. ^ Zhang Y, Zhang X, Zhu H, Liu Y, Cao J, Li D, Ding B, Yan W, Jin H, Wang S (2020). "Identification of Potential Prognostic Long Non-Coding RNA Biomarkers for Predicting Recurrence in Patients with Cervical Cancer". Cancer Management and Research. 12: 719–730. doi:10.2147/CMAR.S231796. PMC 7002755. PMID 32099468.
  24. ^ Zhao H, Zhang M, Yang X, Song D (August 2021). "Overexpression of long non-coding RNA MIR22HG represses proliferation and enhances apoptosis via miR-629-5p/TET3 axis in osteosarcoma cell". Journal of Microbiology and Biotechnology. 31 (10): 1331–1342. doi:10.4014/jmb.2106.06028. PMC 9705835. PMID 34373436. S2CID 236968341.
  25. ^ Cui Z, An X, Li J, Liu Q, Liu W (August 2018). "LncRNA MIR22HG negatively regulates miR-141-3p to enhance DAPK1 expression and inhibits endometrial carcinoma cells proliferation". Biomedicine & Pharmacotherapy. 104: 223–228. doi:10.1016/j.biopha.2018.05.046. PMID 29775889. S2CID 21735979.
  26. ^ Chen H, Ali M, Ruben A, Stelmakh D, Pak M (April 2020). "E2F6-Mediated Downregulation of MIR22HG Facilitates the Progression of Laryngocarcinoma by Targeting the miR-5000-3p/FBXW7 Axis". Molecular and Cellular Biology. 40 (10). doi:10.1128/MCB.00496-19. PMC 7189097. PMID 32094308.
  27. ^ a b Han M, Wang S, Fritah S, Wang X, Zhou W, Yang N, Ni S, Huang B, Chen A, Li G, Miletic H, Thorsen F, Bjerkvig R, Li X, Wang J (February 2020). "Interfering with long non-coding RNA MIR22HG processing inhibits glioblastoma progression through suppression of Wnt/β-catenin signalling". Brain: A Journal of Neurology. 143 (2): 512–530. doi:10.1093/brain/awz406. PMC 7009478. PMID 31891366.
  28. ^ Su W, Guo C, Wang L, Wang Z, Yang X, Niu F, Tzou D, Yang X, Huang X, Wu J, Chen X, Zou L, Yang Z, Chen G (July 2019). "LncRNA MIR22HG abrogation inhibits proliferation and induces apoptosis in esophageal adenocarcinoma cells via activation of the STAT3/c-Myc/FAK signaling". Aging. 11 (13): 4587–4596. doi:10.18632/aging.102071. PMC 6660029. PMID 31291201.
Retrieved from "https://mdwiki.org/wiki/MIR22HG"